Ulysses Capital
VC Fund
Ulysses Capital is a diversified investment firm.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ulysses Capital invests in
Stages Ulysses Capital invests in
Countries Ulysses Capital invests in
Investment Focus
Industry
- Beauty 1 (17%)
- Energy 1 (17%)
- FinTech 1 (17%)
- Finance 1 (17%)
- Biopharma 1 (17%)
Stage
- Seed 3 (50%)
- Pre-Seed 1 (17%)
- Series C 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- South Korea 4 (67%)
- United States 2 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Pearl Health
|
Pearl Health’s mission is to democratize access to value in healthcare.Pearl empowers primary care physicians to deliver better quality care for their patients at a lower cost via a physician enablement technology platform and a value-based payment model.Pearl’s technology provides visibility into patient panel health, simple financialreporting, and recommendations to deliver care to patients who need it most.To date, we have raised more than $20m from investors including Andreessen Horowitz and AlleyCorp, and we’re working with 300+ physicians and 20,000+ lives in value-based models. | $50M / Series C / Jul 08, 2026 | |
Best Innovation
|
Best Innovation is a manufacturer of cosmetic products intended to offer a safe alternative to harmful skincare chemicals. | $15.8M / Seed / Jan 15, 2025 | |
Oilnow Korea
|
Oilnow Korea provides real-time gas station price comparison information. | Seed / Aug 01, 2022 | |
high-home.com
|
TRDST is an e-commerce platform for luxury furniture. | Seed / Jan 28, 2022 | |
VERTICAH
|
VERTICAH is a growth platform for start-ups that offers alternative financing, venture capital, and asset management services. | $495K / Pre-Seed / Jan 10, 2022 | |
Compass Therapeutics
|
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, developing antibody therapeutics to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain enabled multispecific platforms to empirically identify multispecifics and combinations of antibody therapeuticsthat can be advanced to the clinic. The company's lead product candidate, CTX-009, is a bispecific antibody, which inhibits both DLL4-mediated Notch signaling and VEGF-A signaling. CTX-009 has completed a Phase 1 dose escalation study and is in a Phase 1b study in combination with chemotherapy in patients with solid tumors. The company’s second product candidate, CTX-471, is a novel agonistic antibody of CD137, a co-stimulatory receptor on immune cells. It is currently being evaluated in a Phase 1b study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors, and who subsequently relapsed or progressed after a period of stable disease. Compass’ third product candidate, CTX-8371, is a bispecific antibody that blocks both PD-1 and PD-L1 and is in IND-enabling studies. The company was founded in 2014 and is headquartered in Boston, Massachusetts. | $60.5M / Venture - Series Unknown / Jun 23, 2020 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Ulysses Capital invest in?
Ulysses Capital invests primarily in Beauty, Energy and FinTech startups, most often at Seed and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ulysses Capital last invest?
The most recent investment recorded for Ulysses Capital closed in Jul 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
